Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Símbolo de cotizaciónAVR
Nombre de la empresaAnteris Technologies Global Corp
Fecha de salida a bolsaDec 13, 2024
Director ejecutivoPaterson (Wayne G)
Número de empleados136
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 13
Dirección860 Blue Gentian Road
CiudadEAGAN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal55121
Teléfono16514930606
Sitio Webhttps://anteristech.com/
Símbolo de cotizaciónAVR
Fecha de salida a bolsaDec 13, 2024
Director ejecutivoPaterson (Wayne G)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos